Experimental Rx Helped Lung Cancer Patients Live for Years
Lung cancer is the leading cause of cancer-related death in the US. Advanced lung cancers have spread to other areas of the body and are extremely tough to beat. An experimental therapy may be a game changer.
How Researchers Wiped Out Triple-Negative Breast Cancer
Triple-negative breast cancer is a fast-growing form of the disease that tends to return (recur). But a fresh therapeutic approach was found to be capable of eliminating the disease altogether.
Dual Rx Therapy Stalled Pancreatic Cancer
Good news on the pancreatic cancer front has been slow for some time now. But the situation may have changed, as a new study suggests that a combination of two medications may improve the outlook for patients whose pancreatic cancer has spread.
FDA Approves Pancreatic Cancer Treatment
The US Food and Drug Administration today expanded the approved uses of Abraxane (paclitaxel protein-bound particles for injectable suspension, albumin-bound) to treat patients with late-stage (metastatic) pancreatic cancer.
New Life For Advanced Cancer Patients
Gemzar (gemcitabine) is the standard of care for pancreatic cancer. Results from a trial showed that adding another medication worked even better.
Breast Cancer Drug on Route for Melanoma
A phase III trial for a melanoma treatment drug, which is already on the market for breast and lung cancer, has shown promise. The next step is Food and Drug Administration approval for melanoma.
Breast Cancer Drug Gets Green Light for Lung Cancer
Since 2005, Abraxane (paclitaxel) has been approved by the Food and Drug Administration to treat breast cancer. Now the drug can also be used for first-line treatment of advanced lung cancer.
Abraxane Shows Positive Progress for Pancreatic Cancer Treatment
Celgene International Sàrl, a subsidiary of Celgene Corporation today announced that its phase III study of Abraxane (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) in combination with gemcitabine in treatment-naïve patients with advanced pancreatic cancer met its primary endpoint of overall survival.
Newer, More Expensive Drugs Not Better
After the long process of designing, developing and testing new drugs, these meds are usually far more expensive than the older medications on the market. Are they better? Not always.
Nanotechnology and Medicine
Like so much of technology, the hype and fear around nanoparticles says they will either revolutionize the world we live in or embody the newest high tech scourge. The truth is somewhere in the middle, but both sides have valid points.